Related Experiment Video
Updated: Jul 16, 2026
09:41
Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
Published on: February 25, 2021
23.0K
PLGA nanocapsules as a delivery system for a recombinant LRP-based therapeutic
Martin Bernert1, Monique J Bignoux1, Chandni Madhav1
1School of Molecular and Cell Biology, University of the Witwatersrand, Johannesburg, South Africa.
FEBS Open Bio
|May 3, 2024
Summary
Laminin receptor precursor (LRP) protein shows therapeutic potential for age-related diseases. Nanoencapsulation of LRP protein in PLGA nanocapsules safely increases telomerase activity and cell viability.
Area of Science:
- Biogerontology
- Biomaterials Science
- Cell Biology
Background:
- Telomere length maintenance is crucial for cellular aging and age-related diseases.
- Laminin receptor precursor (LRP) protein influences telomerase activity and has therapeutic potential.
- Current methods like plasmid transfection for LRP upregulation are not clinically viable.
Purpose of the Study:
- To develop a safe and effective method for delivering LRP protein to increase telomerase activity.
- To investigate the therapeutic potential of nanoencapsulated LRP for age-related conditions.
Main Methods:
- Synthesized poly(lactic-co-glycolic acid) (PLGA) nanocapsules using double emulsification-solvent evaporation.
- Purified nanocapsules via filtration and centrifugation to achieve optimal size.
- Determined encapsulation efficiency using the BCA assay.
- Assessed the effects of nanoencapsulated LRP on HEK-293 cell viability, LRP levels, and telomerase activity.
Main Results:
- Successfully synthesized and characterized PLGA nanocapsules containing LRP protein.
- Demonstrated a significant increase in cellular LRP protein levels post-treatment.
- Observed a concomitant significant increase in cell viability and telomerase activity.
- Confirmed the safety and efficacy of nanoencapsulated LRP in a cell culture model.
Conclusions:
- Nanoencapsulated LRP protein offers a promising, safer alternative to plasmid transfection for treating age-related diseases.
- This delivery system enhances LRP protein levels, cell viability, and telomerase activity.
- Further research into LRP-based therapies could revolutionize the management of aging and associated pathologies.
More Related Videos
Related Concept Videos
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...